Dienogest reduces HSD17β1 expression and activity in endometriosis
نویسندگان
چکیده
منابع مشابه
Dienogest in long-term treatment of endometriosis
Endometriosis is a chronic disease primarily affecting women of childbearing age, in which endometriotic lesions form outside the uterus, typically leading to painful symptoms, fatigue, and infertility. The symptoms of endometriosis may cause significant impairment in quality of life and represent a substantial economic burden to patients, families, and society. There is no cure for endometrios...
متن کاملDienogest in the Treatment of Endometriosis
Endometriosis is a common disease in up to 10% of women of reproductive age. It often causes symptoms such as dysmenorrhea, chronic pelvic pain, dyspareunia and dyschezia [1]. It is also associated with ovarian endometrioma which requires surgery for both diagnosis and treatment. However, recurrence rates are approximately 30-50% within 5 years after surgery [2]. Dienogest is a new synthetic or...
متن کاملDienogest in the treatment of endometriosis.
INTRODUCTION Dienogest (DNG) is an oral progestin, derivative of 19-nortestosterone, that has recently been introduced for the treatment of endometriosis. AREAS COVERED This review examines the clinical efficacy, safety and tolerability of DNG in the treatment of endometriosis. The material included in the current manuscript was searched and obtained via Medline, Pubmed and EMBASE, from incep...
متن کاملDienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission.
OBJECTIVE To evaluate the effectiveness of dienogest in controlling pain caused by deep infiltrating endometriosis (DIE), its influence on the quality of live (QoL) of women affected by the disease, and the effect of the drug on the volume of endometriotic lesions. STUDY DESIGN A prospective cohort study including 30 women with a sonographic diagnosis of DIE (intestinal and posterior fornix) ...
متن کاملSafety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program
BACKGROUND In four randomized, controlled, European trials, dienogest 2 mg once daily demonstrated significant efficacy for lesion reduction and reduction in pain intensity in endometriosis. We describe a pooled analysis of the safety and tolerability data from these trials to confirm and further characterize the safety profile of dienogest in the treatment of endometriosis. METHODS All 332 w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Endocrinology
سال: 2015
ISSN: 0022-0795,1479-6805
DOI: 10.1530/joe-15-0052